Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,201–1,300 of 2,656
Optimising renal risk parameters in type 2 diabetes mellitus: Perspectives from a retinal viewpoint
Jacob, S., & Varughese, G. I. (2024) · Clinical Medicine · doi:10.1016/j.clinme.2024.100031 · Cited by 4
Miyaoka, Y., Moriyama, T., Saito, S., Rinno, S., Kato, M., Tsujimoto, R., Suzuki, R., China, R., Nagai, M., & Kanno, Y. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000538589 · Cited by 4
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome
Ge, M., Molina, J., Tamayo, I. M., Zhang, G., Kim, J., Njeim, R., Fontanesi, F., Pieper, M. P., Merscher, S., Sharma, K., et al. (2024) · Kidney360 · doi:10.34067/kid.0000000000000472 · Cited by 5
Huang, L., Hu, R., & Zou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419729 · Cited by 4
Meier, N., Laager, R., Gregoriano, C., Schütz, P., Müeller, B., Struja, T., & Kutz, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084526 · Cited by 6
Kao, Y., Yen, K., Chen, S., Chao, T., & Chan, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15734 · Cited by 7
Keum, Y., Caramori, M. L., Cherney, D. Z. I., Crandall, J. P., de Boer, I. H., Lingvay, I., McGill, J. B., Polsky, S., Pop‐Busui, R., Rossing, P. R., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000567 · Cited by 4
Chronic Kidney Disease—Part 1: Evaluation & Risk Assessment in CKD, Methods to Delay CKD Progression
Larsen, D., Varanasi, L., & Estrella, M. M. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.07.004 · Cited by 5
Editorial for the Special Issue: Pathophysiology of Chronic Kidney Disease and Its Complications
Oe, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12020416 · Cited by 4
“Recently, a new class of anti-hyperglycemic drugs, sodium-glucose co-transporter 2 (SGLT2) inhibitors, has shown promise in protecting the kidneys and heart of patients with CKD, both with and without diabetes [18,19].”
Zaman, M. A., & Kalsoom, S. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2390921 · Cited by 5
SGLT2 inhibitors: Exploring the effects in humans and horses
Sundra, T., Matthews, V. B., Harris, P. A., & Rendle, D. I. (2024) · Equine Veterinary Education · doi:10.1111/eve.14071 · Cited by 3
Tan, B. W. L., Tan, B. W. Q., Akalya, K., Hong, W.-Z., Da, Y., Low, S., Ng, W.-Y., & Chua, H. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.100996 · Cited by 3
Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review
Peña, C., Flores, J., & NUGENT, K. M. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09607-7 · Cited by 6
Galli, K. J., Wadid, M., & Bessada, Y. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001703 · Cited by 3
Haq, N., Uppal, P., Abedin, T., & Lala, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093213 · Cited by 7
Mosalam, E. M., AboShabaan, H. S., Mahfouz, M. M., Sallam, A. S., Elhosary, E., Allam, A., Metwally, E. M., Shaldam, M. A., & Ghoneim, M. E.-S. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117382 · Cited by 6
Hoxha, A., Prete, D. D., Condonato, I., Martino, F. K., Lovisotto, M., Nalesso, F., & Simioni, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103326 · Cited by 5
“Sodium–glucose cotransporter inhibitors (iSGLT-2) have transformed chronic kidney disease (CKD) management but have not been tested for aPL-N due to exclusions in recent trials [82,83].”
Gao, X., Xiao, D., Wang, W., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.164174 · Cited by 3
Enhancing therapeutic strategies and drug development for patients with kidney disease
Tsang, Y. P., Aryeh, K. S., Wang, K., Himmelfarb, J., Yeung, C. K., & Kelly, E. J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2525970 · Cited by 4
SGLT2 inhibitors for kidney protection in children: expanding horizons beyond endocrinology
Pucci, C., Marazza, D. S., Preka, E., Mastrangelo, A., Montini, G., & Boyer, O. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-06838-7 · Cited by 8
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 9
Møller, C. A., Nielsen, S. F., & Mose, F. H. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf130 · Cited by 3
Opportunities and challenges in the treatment of IgA nephropathy
Yang, Y., & Xu, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1559593 · Cited by 6
Karalliedde, J. J., McCafferty, K., Winocour, P. H., Chowdhury, T. A., Kanumilli, N., De, P., Frankel, A., Doherty, C., Milne, N., Montero, R., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.07.028 · Cited by 4
Georgianos, P. I., Koufakis, T., Arampatzis, S., & Liakopoulos, V. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70026 · Cited by 3
Tsai, M., Lee, W., Huang, S., Huang, C.-C., Wang, Y., Yuan, C., Wang, C.-C., Liu, C.-H., Huang, N., Chang, Y., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117512 · Cited by 3
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 7
SGLT2 inhibition attenuates diabetic tubulopathy by suppressing SGK1-mediated pyroptosis
Shi, X., Zou, W., Li, X., Liu, S., Hu, T., Li, Q., Zhang, T., Chen, L., Wu, S., Wang, C., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1620230 · Cited by 6
Antiarrhythmic potential of SGLT2 inhibitors: Mechanistic insights and clinical evidence
Fujiki, S. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.09.018 · Cited by 6
Hitting the Sweet Spot: A Review of SGLT2i in Cardiovascular Medicine
Zayyad, Z. A., Gupta, N., Roy, A., Kalagara, S., Mishra, A., Salem, E., Seshadri, S. R., Gichi, D., Hammad, B., Ene, A., et al. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00436-2 · Cited by 4
Shlyakhto, E. V., Arutyunov, G. P., Batyushin, М. М., Вадимовна, В. С., Звартау, Н. Э., Nedogoda, S. V., Em, S., Soloveva, A. E., Медведева, Е. А., Zorina, E. A., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6515 · Cited by 5
Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice
Vilardell-Vilà, J., Jacobs-Cachá, C., Martos-Guillamí, N., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.026 · Cited by 3
Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients
Anderson, E., Shabanowitz, S., Jessup, K., Allen, R. B., Chandran, M. M., & Yang, A. (2025) · Clinical Transplantation · doi:10.1111/ctr.70365 · Cited by 3
“Previous studies, which excluded KTRs, have shown that meaningful preservation of eGFR around 14–18 months in a patient population with higher baseline albuminuria (mostly UACR > 300 mg/g) [15].”
InfluentialMatarneh, A. S., Salameh, O. K. M., Koirala, M., Karasinski, A. A., Kaur, G., Trivedi, N., Ghahramani, N., & Shah, V. H. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71474 · Cited by 3
Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome
Zhu, H., Zheng, L., Zhao, K., Wang, X., Ma, Z., Zeng, A., Zhao, W., Zhang, W. Y., Han, L., & Huang, Y. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/3340719 · Cited by 9
Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial
Vajgel, G., Júnior, B. M. D. S., Filho, C. R., de Oliveira, C. B. L., Costa, D. M. D. N., de Lima, C. A. D., Valente, L. M., & Sandrin‐Garcia, P. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf257 · Cited by 7
Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial
Hofherr, A., Maki-Petaja, K. M., Selvarajah, V., Grice, D., Bartesaghi, S., Jiménez, E., Pecoits‐Filho, R., & Heerspink, H. J. L. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000966 · Cited by 6
Navarrete, R. E. T., Freitas, J. C., Fonseca, I. M., Cunha, A., Sa, J. R., & Martins, L. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010181 · Cited by 3
Causland, F. R. M., Heerspink, H. J. L., Vaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., McGrath, M. M., Rohwedder, K., Amarante, F., BRINKER, M. D., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000849 · Cited by 4
Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 7
Badran, A., Gbreel, M. I., Tawfik, A. M., & Balata, M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02080-1 · Cited by 3
“These renoprotective effects of SGLT-2i align with the results of landmark trials like CREDENCE, DAPA-CKD, and EMPA-KIDNEY [45–47].”
Verma, S., Katwal, S., Akula, H. R., Inamdar, A., Kundukulam, S. S., Khan, M., Satti, A. B. A. Q., Menon, S., & Rai, M. (2026) · Cureus · doi:10.7759/cureus.101867 · Cited by 4
“Similarly, the EMPA-KIDNEY trial reported a 28% reduction in kidney disease progression or cardiovascular death across a broad CKD population [48].”
Azegami, T., Kaneko, H., Okada, A., Suzuki, Y., Ko, T., Aoyama, K., Nakayama, T., Kimura, Y., Fujiu, K., Takeda, N., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70502 · Cited by 3
“7,8 This discrepancy highlights an important evidence gap: many older adults with DKD in routine clinical practice have more heterogeneous clinical profiles, including lower levels of albuminuria or higher age than typical RCT participants.”
Prescription Patterns of Sodium-Glucose Co-Transporter 2 Inhibitors among Nephrologists
Gopal, A., Nair, R. R., Kurian, G., Mathew, A., Polachirakal, Z. P., & Seetha Lakshmy, K. D. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_784_2025 · Cited by 3
Registro Español de Diálisis y Trasplante (REDYT): informe del año 2023 y análisis evolutivo
Quiroga, B., Mahíllo, B., Mazuecos, A., Ortiz, A., Troya, M. I., Hernández-Marrero, D., Alemán, S. T., Santiuste, C., Arévalo, O. L. R., Marqués-Vidas, M., et al. (2026) · Nefrología · doi:10.1016/j.nefro.2026.501510 · Cited by 4
Kramer, H. J., & Bakris, G. L. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70066 · Cited by 4
Hyder, S. N., Seth, M., Hamilton, D. E., Stoute, H., Daher, E., Chattahi, J., Samman, B., Gupta, V., Briguori, C., Rudnick, M. R., et al. (2026) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.125.015645 · Cited by 3
Optimal patient care in advanced chronic kidney disease progressing to kidney failure
Combe, C., de Pinho, N. A., Guedes, M. H., Frimat, L., Fouque, D. P., Liabeuf, S., Niang, A., Kanjanabuch, T., Stengel, B., Massy, Z. A., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01056-2 · Cited by 10
“Evidence of benefit in people transitioning to kidney failure is more limited, as people with very low GFR were excluded from key RCTs (the DAPA-CKD trial 99 excluded patients with eGFR 25 ml/min/1.73 m 2 and those with eGFR 20 ml/min/ 1.73 m 2 were excluded from the EMPA-KIDNEY trial 100,101 ).”
InfluentialAssociation of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure
Hacil, A., Piccoli, M., Antakly, Y., Guglieri, M., Lochon, L., Duneton, S., Hanon, O., & Fauchier, L. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag038 · Cited by 4
Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF
Sauer, A. J., ter Maaten, J. M., & Savarese, G. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag056 · Cited by 5
Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?
Weir, M. R. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151688 · Cited by 4
Dahl, N. K., August, P., Besse, W., Chebib, F. T., Chonchol, M., Cowley, B. D., Göral, S., Guay‐Woodford, L. M., Gulati, A., Hogan, M. C., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.11.006 · Cited by 4
Keskin, B., Hakgör, A., Khidolda, Y., Dursun, A., Akhundova, A., Savur, Ü., Olgun, F. E., Onder, O., Beşiroğlu, M., Dursun, M. Z., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1799940 · Cited by 4
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone
Agarwal, R., Correa‐Rotter, R., Navaneethan, S. D., Fukami, K., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001071 · Cited by 3
Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment
Zoccali, C., Caterina, R. D., Tuttle, K. R., Burnier, M., Massy, Z. A., Mallamaci, F., Ferro, C. J., & Zannad, F. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag220 · Cited by 5
Global kidney health: Are we failing the silent pandemic?
Yi, T. W., O’Hara, D. V., & Levin, A. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70088 · Cited by 5
Farmakis, D. T., Karampinos, K. I., Kapelios, C. J., Liori, S., Fountoulaki, K., & Filippatos, G. S. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag061 · Cited by 3
Cherney, D. Z. I., Alicic, R. Z., & Bonaca, M. P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.01.010 · Cited by 7
Lee, E. M., Cho, I., Kang, H., Kim, K., Kim, D., Kim, J. H., Kim, H., Kim, H. C., Kim, H. J., Koh, E. S., et al. (2026) · Clinical Hypertension · doi:10.5646/ch.2026.32.e31 · Cited by 7
Jobanputra, R., Sargeant, J. A., Plekhanova, T., James, E., Almaqhawi, A., Webb, D. R., Davies, M. J., & Yates, T. E. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70194 · Cited by 10
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Dapagliflozin in people with chronic kidney disease
Sylvester, R. D., & Khong, T. K. (2023) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2023.000022 · Cited by 3
How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors
Gunasekaran, D., & Shirali, A. C. (2023) · Kidney360 · doi:10.34067/kid.0000000000000219 · Cited by 3
Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations
Ha, K. H., & Kim, D. J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14111 · Cited by 3
Li, L., Dong, Y.-H., Bai, Y. S., Tang, Z., Deng, Y.-M., Wu, Z., & Li, W. (2023) · Endocrine · doi:10.1007/s12020-023-03618-x · Cited by 4
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
“31 In addition to CKD, attenuation of injury markers in the proximal tubules of the kidney may have a role in protection against acute kidney injury.”
BackgroundZhang, A., Kalil, R. K., Marzec, A., Coulter, S., Virani, S. S., Patel, K. V., & Segar, M. W. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-23-8375 · Cited by 5
König, S., Pellissier, V., Hohenstein, S., Leiner, J., Schanner, C., Kwast, S., Müller, M., Kuhlen, R., & Bollmann, A. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14827 · Cited by 4
Kim, D. H., Lee, M. J., Kang, D., Khang, A. R., Bae, J. H., Kim, J. Y., Kim, S. H., Kang, Y. H., & Yi, D. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070445 · Cited by 4
Ahmed, R. M., Rakha, N. K., Yousry, A., & Soliman, A. R. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00352-2 · Cited by 4
Chen, L., Zuo, Y., He, M., Duo, L., & Tang, W. (2024) · Journal of International Medical Research · doi:10.1177/03000605241272639 · Cited by 3
Mechanistic Insights of SGLT2 Inhibition in Heart Failure Through Proteomics
Patel, R. B. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.030 · Cited by 3
Empagliflozin: a wonder drug for the treatment of SIAD?
Tzoulis, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1453159 · Cited by 5
Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands
Slob, B. P. H., Fens, T., Weersma, M., Postma, M. J., Boersma, C., & de Jong, L. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0315509 · Cited by 4
Trillini, M., Jenssen, T. G., Martin, W. P., & Morales, E. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf008 · Cited by 5
Rashid, S. A., Madar, I. H., Misbah, I., Dhanabalan, K., Balasubramanian, R., & Maideen, N. M. P. (2025) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.1055/s-0045-1805026 · Cited by 4
Aylward, R. E., Hayward, S., Chesnaye, N. C., Janse, R. J., Jonsson, P. A., Torino, C., Vilasi, A. D., Szymczak, M., Drechsler, C., Dekker, F. W., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf079 · Cited by 4
“Currently available therapeutics to control traditional cardiovascular risk factors are limited as CKD progression is only modestly ameliorated especially in persons with established advanced CKD [4 , 5 ].”
Marinho, L. L., Ribeiro, M. L., Lawler, P. R., Iatan, I., Godoy, L. C., Rached, F. H., & Maranhão, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01292-0 · Cited by 3
“Renin-angiotensin system blockers [ 85–87], SGLT2 inhibitors [88–90], and mineralocorticoid antagonists [91–93] are established pillars for slowing disease progression and improving renal outcomes.”
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004007 · Cited by 5
“odium glucose cotransporter 2 inhibitors (SGLT2i) are effective treatments of both type 2 diabetes mellitus (DM2) and chronic kidney disease (CKD), reducing the risk of cardiovascular events and progression of renal disease, irrespective of diabetes status [1–4].”
Auswirkungen „neuer“ Antidiabetika auf das Anästhesiemanagement
Rupprecht, B., & Dumps, C. (2025) · Die Anaesthesiologie · doi:10.1007/s00101-025-01521-w · Cited by 3
Huang, B., Kao, Y.-W., Yen, K., Chen, S., Chao, T., & Chan, Y. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf133 · Cited by 2
Canagliflozin‐induced renal glutathione distribution mapping in non‐diabetic male rat kidneys
Watanabe, G., Horita, S., Moriya, R. F., Masuishi, Y., Misaka, S., Taira, S., Shimomura, K., Shimabukuro, M., & Kazama, J. J. (2025) · Physiological Reports · doi:10.14814/phy2.70320 · Cited by 3
Llorens‐Soriano, P., Haro, A., Gil, V., et al. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502300 · Cited by 3
Ngan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112278 · Cited by 3
Lee, H., Jhee, J. H., Kim, E., Son, D., Kim, H. C., Lloyd‐Jones, D. M., & Lee, H. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.024 · Cited by 3
Schechter, M., Cohen, Y., Fishkin, A., Mosenzon, O., Leibowitz, G., & Aharon‐Hananel, G. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112338 · Cited by 3
Kędzierska-Kapuza, K., Grudniewska, A., Durma, A. C., Małecki, R., Franek, E., & Szczuko, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134701 · Cited by 5
Multifactorial chronic kidney disease
Guerra, J. M. A., & Martinez-Martinez, J.-I. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf122 · Cited by 6
Joseph, J. (2025) · Cureus · doi:10.7759/cureus.87399 · Cited by 3
“Interestingly, both groups exhibited minor reductions in eGFR, which is expected in the early phase due to a reduction in intraglomerular pressure within the kidneys but ultimately stabilizes with long-term therapy [5].”
Optimizing care for chronic kidney disease: Considerations from A to Z
Chen, F.-Y., Chang, W., Kao, Z.-K., Tan, A. C., Li, S., Yang, C.-Y., Lin, H., & Lin, C.-C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001280 · Cited by 7
Zac‐Varghese, S. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100512 · Cited by 5
Progressionshemmung bei chronischen Nierenerkrankungen
Saritas, T., & Floege, J. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01482-5 · Cited by 6
Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF): Diagnose und Therapie
Morbach, C., & Störk, S. (2023) · Herz · doi:10.1007/s00059-022-05156-0 · Cited by 3
Miñana, G., de la Espriella, R., Palau, P., Amiguet, M., Seller, J., Pinilla, J. M. G., Núñez, E., Górriz, J. L., Valle, A., Sanchís, J. M., et al. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.03.007 · Cited by 5
Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease
Terpening, C. M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231165774 · Cited by 6
“52 This trial enrolled patients with eGFR 20 to 45 irrespective of albuminuria or eGFR 45 to 90 with albuminuria.”
BackgroundSGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease
Kristensen, S. L., Jensen, J., & Schou, M. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.389 · Cited by 3
Safety of SGLT2i with regard to bone and mineral metabolism in patients with CKD
Kazé, A. D., Patorno, E., & Paik, J. M. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000887 · Cited by 3
The Landscape of IgA Nephropathy Treatment Strategy: A Pharmacological Overview
Leo, V. D., Annese, F., Papadia, F., Cara, I., Giliberti, M., Sallustio, F., & Gesualdo, L. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3020033 · Cited by 5
“The rates of serious adverse events were similar in the two groups [77].”
BackgroundDiabetes og kronisk nyresykdom
Mariampillai, J. E., Halvorsen, L. V., Larstorp, A. C. K., Heimark, S., Waldum-Grevbo, B. E., Kjeldsen, S. E., Nordby, G., Stenehjem, A., Berg, J. P., & Høieggen, A. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0822 · Cited by 4
Barreto, J., Campos‐Staffico, A. M., Nadruz, W., Quinaglia, T., & Sposito, A. C. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1243530 · Cited by 4
“001) in the DAPA-CKD and EMPA-KIDNEY trial, respectively (86, 87).”
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.